Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
The DOI matches its Crossref record; 28 of the 31 references it cites were found in a registry or an index.
Abstract
Apoptosis is a genetically encoded programme of cell death that can be activated under physiological conditions and may be an important safeguard against tumour development. Regions of low oxygen (hypoxia) and necrosis are common features of solid tumours. Here we report that hypoxia induces apoptosis in oncogenically transformed cells and that further genetic alterations, such as loss of the p53 tumour-suppressor gene or overexpression of the apoptosis-inhibitor protein Bcl-2, substantially reduce hypoxia-induced cell death. Hypoxia also selects for cells with defects in apoptosis, because small numbers of transformed cells lacking p53 overtake similar cells expressing wild-type p53 when treated with hypoxia. Furthermore, highly apoptotic regions strongly correlate with hypoxic regions in transplanted tumours expressing wild-type p53, whereas little apoptosis occurs in hypoxic regions of p53-deficient tumours. We propose that hypoxia provides a physiological selective pressure in tumours for the expansion of variants that have lost their apoptotic potential, and in particular for cells acquiring p53 mutations.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Giaccia and co-workers demonstrated that hypoxia can induce tumor cell apoptosis, an effect that was reduced by loss of p53 tumor suppressor function or overexpression of anti-apoptotic Bcl-2 (Graeber et al., 1996).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
In the citing paper
“Therefore, hypoxia can exert a selective pressure that leads to expansion of tumor cells with reduced apoptotic capacity due to, for example, TP53 mutations (Graeber et al., 1996).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
In the citing paper
“Hypoxia and/or HIFs can mediate chemotherapy resistance through additional mechanisms including: a) hypoxia-induced decreases in tumor cell proliferation (Tannock, 1968); b) metabolic reprogramming; c) hypoxia-driven selection of p53-mutated tumor cells with less apoptotic capacity (Graeber et al., 1996); and d) inhibition of DNA damage (Sullivan & Graham, 2009).”
From Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer (2016) · cites this paper as Graeber et al., 1996
Citations
Cites
Apoptosis in the Pathogenesis and Treatment of Disease
Thompson, C. B. (1995) · Science · doi:10.1126/science.7878464 · Cited by 6,524
Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death
Hockenbery, D., Nuñez, G., Milliman, C., Schreiber, R. D., & Korsmeyer, S. J. (1990) · Nature · doi:10.1038/348334a0 · Cited by 3,720
Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.
Greenblatt, M. S., Bennett, W. P., Hollstein, M., & Harris, C. C. (1994) · PubMed · Cited by 3,463
p53-dependent apoptosis modulates the cytotoxicity of anticancer agents
Lowe, S. W., Ruley, H. E., Jacks, T., & Housman, D. E. (1993) · Cell · doi:10.1016/0092-8674(93)90719-7 · Cited by 2,925
Self-citationDranoff, G., Jaffee, E., Lazenby, A., Golumbek, P., Levitsky, H., Brose, K., Jackson, V, Hamada, H., Pardoll, D., & Mulligan, R. C. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.8.3539 · Cited by 2,818
Production of high-titer helper-free retroviruses by transient transfection.
Pear, W. S., Nolan, G. P., Scott, M. L., & Baltimore, D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.18.8392 · Cited by 2,266
The Histological Structure of Some Human Lung Cancers and the Possible Implications for Radiotherapy
Thomlinson, R. H., & Gray, L. H. (1955) · British Journal of Cancer · doi:10.1038/bjc.1955.55 · Cited by 2,219
Mice Lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control
Deng, C., Zhang, P., Wade Harper, J., Elledge, S. J., & Leder, P. (1995) · Cell · doi:10.1016/0092-8674(95)90039-x · Cited by 2,113
The Molecular Genetics of Cancer
Bishop, J. M. (1987) · Science · doi:10.1126/science.3541204 · Cited by 1,688
Sunburn and p53 in the onset of skin cancer
Ziegler, A., Jonason, A. S., Leffellt, D. J., Simon, J. A., Sharma, H. W., Kimmelman, J., Remington, L., Jacks, T., & Brash, D. E. (1994) · Nature · doi:10.1038/372773a0 · Cited by 1,497
Self-citation
Research works printed but not linked: 9
- Vaupel, P. W. & Hockel, M. in Tumor Oxygenation (eds Vaupel, P. W., Kelleher, D. K. & Gunderoth, M.) 219–232 (Gustav Fischer, Stuttgart, 1995).
- Lord, E. M., Harwell, L. & Koch, C. J. Cancer Res. 53, 5721–5726 (1993).
- Bardeesy, N., Beckwith, J. B. & Pelletier, J. Cancer Res. 55, 215–219 (1995).
- Baker, S. J. et al. Cancer Res. 50, 7717–7722 (1990).
- Sinicrope, F. A. et al. Cancer Res. 55, 237–241 (1995).
- Bedi, A. et al. Cancer Res. 55, 1811–1816 (1995).
- Lotem, J. & Sachs, L. Cell Growth. Differ. 4, 41–47 (1993).
- Lowe, S. W. Curr. Opin. Oncol. (in the press).
- Greenblatt, M. S., Bennett, W. P., Hollstein, M. & Harris, C. C. Cancer Res. 54, 4855–4878 (1994).
Cited by
Items 601–700 of 1,006
Hypoxia-induced and stress-specific changes in chromatin structure and function
Johnson, A. B., & Barton, M. C. (2007) · Mutation research. Fundamental and molecular mechanisms of mutagenesis · doi:10.1016/j.mrfmmm.2006.10.007 · Cited by 114
Inhibition of ATR Leads to Increased Sensitivity to Hypoxia/Reoxygenation
Hammond, E. M., Dorie, M. J., & Giaccia, A. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1520 · Cited by 101
Self-citationCell cycle regulators: mechanisms and their role in aetiology, prognosis, and treatment of cancer.
Michalides, R. J. A. M. (1999) · Journal of Clinical Pathology · doi:10.1136/jcp.52.8.555 · Cited by 114
Büchler, P., Reber, H. A., Büchler, M. W., Friess, H., Lavey, R. S., & Hines, O. J. (2004) · Cancer · doi:10.1002/cncr.11873 · Cited by 103
neu/ERBB2 Cooperates with p53-172H during Mammary Tumorigenesis in Transgenic Mice
Li, B., Rosen, J. M., McMenamin-Balano, J., Muller, W. J., & Perkins, A. S. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.6.3155 · Cited by 105
“This p53- and p21-dependent G1/S checkpoint may play an important role in vivo to arrest cell growth in the setting of tumor hypoxia (18), and the loss of this pathway may then result in chromosomal reduplication, a hallmark of malignant tumors (70) and a feature of tumors expressing p53-172H.”
BackgroundHypoxia in Breast Cancer—Scientific Translation to Therapeutic and Diagnostic Clinical Applications
Zhang, Y., Zhang, H., Wang, M., Schmid, T., Xin, Z., Kozhuharova, L., Yu, W.-K., Huang, Y., Cai, F., & Biskup, E. M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.652266 · Cited by 114
“The reduced ratio of p53/bcl-2 acts increases mutation rates within a clone population, promoting the oncogenesis of breast cancer (45, 46).”
BackgroundColon cancer: genomics and apoptotic events
Rupnarain, C., Dlamini, Z., Naicker, S., & Bhoola, K. D. (2004) · Biological Chemistry · doi:10.1515/bc.2004.053 · Cited by 122
“With tumour development, hypoxia sets in as the angiogenic rate decreases (Graeber et al., 1996).”
BackgroundLeroy, K., Haïoun, C., Lepage, É., Metayer, N. L., Berger, F., Labouyrie, E., Meignin, V., Petit, B., Bastard, C., Salles, G. A., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf185 · Cited by 103
“The higher frequency of p53 gene mutations in bulky disease might either reflect an increased risk of secondary genetic events parallel to tumoral growth or be related to an increased resistance to hypoxia of p53 mutated cells [44], as it has been suggested in the case of solid tumors [45].”
BackgroundRETRACTED: Role of Autophagy as a Survival Mechanism for Hypoxic Cells in Tumors
Tan, Q., Wang, M., Yu, M., Zhang, J., Bristow, R. G., Hill, R. P., & Tannock, I. F. (2016) · Neoplasia · doi:10.1016/j.neo.2016.04.003 · Cited by 98
“Tumor hypoxia often correlates with poor outcome, and although hypoxic cells in tumors eventually die, there is evidence that they are resistant to apoptosis [12].”
BackgroundRetractedHypoxia-driven intratumor heterogeneity and immune evasion
Terry, S., Engelsen, A. S. T., Buart, S., El‐Sayed, W., Venkatesh, G. H., & Chouaïb, S. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.004 · Cited by 107
Spiotto, M. T., Banh, A., Papandreou, I., Cao, H., Galvez, M. G., Gurtner, G. C., Denko, N. C., Le, Q. T., & Koong, A. C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2747 · Cited by 97
“By contrast, nutrients may become limited in the tumor microenvironment, potentially inhibiting cell growth and/or activating cell death pathways (7).”
A spontaneous murine melanoma lung metastasis comprised of host x tumor hybrids.
Chakraborty, A. K., Sodi, S., Rachkovsky, M., Колесникова, Н. В., Platt, J. T., Bolognia, J. L., & Pawelek, J. M. (2000) · PubMed · Cited by 102
PUMA Sensitizes Lung Cancer Cells to Chemotherapeutic Agents and Irradiation
Yu, J., Yue, W., Wu, B., & Zhang, L. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2429 · Cited by 108
Coopersmith, C. M., O’Donnell, D., & Gordon, J. I. (1999) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.1999.276.3.g677 · Cited by 102
What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors?
Rak, J. W., Yu, J., Kerbel, R. S., & Coomber, B. L. (2002) · PubMed · Cited by 113
Therapeutic implications of tumor interstitial acidification
Kolosenko, I., Avnet, S., Baldini, N., Viklund, J., & Milito, A. D. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.01.008 · Cited by 109
A mathematical model of the stress induced during avascular tumour growth
Jones, A. F., Byrne, H. M., Gibson, J. S., & Dold, J. W. (2000) · Journal of Mathematical Biology · doi:10.1007/s002850000033 · Cited by 111
“tions of tumour cells which contain versions of the gene p53 can survive under abnormally low oxygen (i.e. hypoxia) [ 13 ]. Consequently the size”
BackgroundCompetition and natural selection in a mathematical model of cancer
NAGY, J. (2003) · Bulletin of Mathematical Biology · doi:10.1016/j.bulm.2003.10.001 · Cited by 101
“Perhaps the best understood parameters are those associated with the growth functions � i . Thompson and Royds (1999), using data from Graber et al. (1996) , estimated parameter values for the function � for two different cancer cell lines in culture—a ‘wild-type’ and a mutant that under-expresses p53 (Table 1). These…”
MethodMujčić, H., Rzymski, T., Rouschop, K. M. A., Koritzinsky, M., Milani, M., Harris, A. L., & Wouters, B. G. (2009) · Radiotherapy and Oncology · doi:10.1016/j.radonc.2009.08.017 · Cited by 111
“Moreover, hypoxia contributes to the development of a more malignant tumour phenotype [4–6].”
BackgroundBrizel, D. M., & Esclamado, R. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.2829 · Cited by 112
Burgman, P., O’Donoghue, J. A., Lewis, J. S., Welch, M. J., Humm, J. L., & Ling, C. (2005) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2005.05.003 · Cited by 101
Avila, M. A., Carretero, M. V., Rodriguez, E. N., & Mato, J. M. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70489-5 · Cited by 101
Hoogsteen, I. J., Marres, H. A. M., Bussink, J., van der Kogel, A. J., & Kaanders, J. H. A. M. (2007) · Head & Neck · doi:10.1002/hed.20543 · Cited by 111
“It may thus serve as a physiological selection pressure in tumors by promoting apoptosis in some cells but survival of those cells that have lost their apoptotic potential.(12) The causes of hypoxia are multifactorial and include factors such as abnormal tumor vasculature, impaired blood perfusion, rate of oxygen cons…”
BackgroundParks, D. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.6.1289 · Cited by 99
Tissue biomarkers as prognostic variables of cervical cancer
Gadducci, A., Guerrieri, M. E., & Greco, C. (2012) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.09.003 · Cited by 105
“Tumor hypoxia is a micro-environmental factor related to enetic instability, resistance to apoptosis, invasive growth nd metastatic spread [127–129].”
BackgroundQanungo, S., Wang, M., & Nieminen, A.-L. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406749200 · Cited by 99
Imaging tumor hypoxia by magnetic resonance methods
Pacheco‐Torres, J., López‐Larrubia, P., Ballesteros, P., & Cerdán, S. (2010) · NMR in Biomedicine · doi:10.1002/nbm.1558 · Cited by 105
“environmental pressure has been proposed as the driving force for the natural selection of resistant cells depicting a more malignant and metastatic phenotype (36,50).”
BackgroundThe relationship between hypoxia and angiogenesis
Moeller, B. J., Cao, Y., Vujašković, Ž., Li, C. Y., Haroon, Z. A., & Dewhirst, M. W. (2004) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2004.04.005 · Cited by 99
Angiogenesis and non-small cell lung cancer
Cox, G., Jones, J. L., Walker, R. A., Steward, W. P., & O'Byrne, K. J. (2000) · Lung Cancer · doi:10.1016/s0169-5002(99)00096-3 · Cited by 106
Angiogenic Potential of Prostate Carcinoma Cells Overexpressing bcl-2
Fernandez, A., Udagawa, T., Meyer‐Schwesinger, C., Beecken, W.-D., Achilles-Gerte, E., McDonnell, T. J., & D’Amato, R. J. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.3.208 · Cited by 99
“However, hypoxic stress can also exert a selective pressure within tumors that supports the expansion of cells with mutations that reduce the apoptotic potential of those cells ( 8 ).”
BackgroundImaging Tumor Hypoxia to Advance Radiation Oncology
Lee, C.-T., Boss, M., & Dewhirst, M. W. (2013) · Antioxidants and Redox Signaling · doi:10.1089/ars.2013.5759 · Cited by 107
“This selection will lead to tumor cell resistance to apoptotic stimuli (81, 250).”
Hypoxia-mediated drug resistance in breast cancers
McAleese, C. E., Choudhury, C., Butcher, N. J., & Minchin, R. F. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.11.045 · Cited by 106
Hypoxia-Mediated Up-Regulation of Pim-1 Contributes to Solid Tumor Formation
Chen, J., Kobayashi, M., Darmanin, S., 高橋, 義., Gully, C., Zhao, R., Kondo, S., Wang, H., Wang, H., Yeung, S. J., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080972 · Cited by 101
Barthel, H., Wilson, H., Collingridge, D. R., Brown, G., Osman, S., Luthra, S. K., Brady, F., Workman, P., Price, P. M., & Aboagye, E. O. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601862 · Cited by 92
“Detection of hypoxia is important because hypoxia is a powerful trigger for gene expression and thus clonal selection of a more aggressive phenotype, for example, diminished apoptotic potential (Gräber et al, 1996; Koong et al, 2000).”
BackgroundSumiyoshi, Y., Kakeji, Y., Egashira, A., Mizokami, K., Orita, H., & Maehara, Y. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2382 · Cited by 109
p53 cannot be induced by hypoxia alone but responds to the hypoxic microenvironment
Pan, Y., Oprysko, P. R., Asham, A. M., Koch, C. J., & Simon, M. C. (2004) · Oncogene · doi:10.1038/sj.onc.1207657 · Cited by 108
“In direct contrast, tumors expressing mutant p53 exhibit significantly lower levels of apoptosis in hypoxic domains (Graeber et al., 1996; StempienOtero et al., 1999).”
BackgroundSelf-citationTissue oxygen distribution in head and neck cancer patients
Adam, M., Gabalski, E. C., Bloch, D. A., Oehlert, J. W., Brown, J. M., Elsaid, A. A., Pinto, H. A., & Terris, D. J. (1999) · Head & Neck · doi:10.1002/(sici)1097-0347(199903)21:2<139::aid-hed7>3.0.co;2-p · Cited by 98
p53 modulates base excision repair activity in a cell cycle-specific manner after genotoxic stress.
Offer, H., Zurer, I., Bánfalvi, G., Rehak, M., Falcovitz, A., Milyavsky, M., Goldfinger, N., & Rotter, V. (2001) · PubMed · Cited by 98
Gastric Cancer and Angiogenesis: Is VEGF a Useful Biomarker to Assess Progression and Remission?
Macedo, F., Ladeira, K., Longatto‐Filho, A., & Martins, S. F. F. (2017) · Journal of the Korean Gastric Cancer Association · doi:10.5230/jgc.2017.17.e1 · Cited by 97
“Hypoxia can also induce p53 that lacks its function and shows diminished apoptotic potential [38].”
BackgroundCiaparrone, M., Quirino, M., Schinzari, G., Zannoni, G. F., Corsi, D. C., Vecchio, F. M., Cassano, A., Torre, G. L., & Barone, C. A. (2006) · Oncology · doi:10.1159/000098110 · Cited by 97
Bcl-2 Mediates Chemoresistance in Matched Pairs of Primary Eμ-myc Lymphomas in Vivo
Schmitt, C. A., & Lowe, S. W. (2001) · Blood Cells Molecules and Diseases · doi:10.1006/bcmd.2000.0372 · Cited by 104
Self-citationRole of the hypoxic bone marrow microenvironment in 5T2MM murine myeloma tumor progression.
Asosingh, K., Raeve, H. D., Ridder, M. D., Storme, G. A., Willems, A., Riet, I. V., Camp, B. V., & Vanderkerken, K. (2005) · PubMed · Cited by 109
Rajnakova, A., Moochhala, S., Goh, P. M. Y., & Ngoi, S. S. (2001) · Cancer Letters · doi:10.1016/s0304-3835(01)00645-0 · Cited by 100
Nylander, K., Bourdon, J.-C., Bray, S. E., Gibbs, N. K., Kay, R., Hart, I., & Hall, P. A. (2000) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(200001)190:1<39::aid-path492>3.0.co;2-v · Cited by 98
“The best-characterized inducer of p53 activity is genotoxic insult, but other insults such as hypoxia [12], cytokines and growth factors [13], loss of cell anchorage [14], metabolic alterations [15], and oncogenes [16] have also been shown to induce p53 activity.”
BackgroundHistology-Based Expression Profiling Yields Novel Prognostic Markers in Human Glioblastoma
Dong, S., Nutt, C. L., Betensky, R. A., Stemmer-Rachamimov, A. O., Denko, N. C., Ligon, K. L., Rowitch, D. H., & Louis, D. N. (2005) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/01.jnen.0000186940.14779.90 · Cited by 96
“Extensive, careful recent work has investigated this histologic phenomenon and has demonstrated that these palisades represent a dynamic response to local hypoxic stresses (12, 13), the types of stresses that have been associated with clonal selection pressures in human tumors (14).”
BackgroundCurrent topics of physiology and pharmacology in the lymphatic system
Ohhashi, T., Mizuno, R., Ikomi, F., & Kawai, Y. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2004.10.009 · Cited by 97
Mangraviti, A., Raghavan, T., Volpin, F., Skuli, N., Gullotti, D., Zhou, J., Asnaghi, L., Sankey, E., Liu, A., Wang, Y., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-14990-w · Cited by 93
Regulation of Programmed Cell Death by the P53 Pathway
Kuribayashi, K., & El‐Deiry, W. S. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-1-4020-6554-5_10 · Cited by 110
Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair.
Kondo, A., Safaei, R., Mishima, M., Niedner, H., Lin, X., & Howell, S. B. (2001) · PubMed · Cited by 95
Raynaud, C. M., Sabatier, L., Philipot, O., Olaussen, K. A., & Soria, J. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2007.11.006 · Cited by 106
“Several models have een proposed to explain this high frequency of p53 inactiation [88,89].”
BackgroundCytotoxicity of Paclitaxel Incorporated in PLGA Nanoparticles on Hypoxic Human Tumor Cells
Jin, C. S., Bai, L., Wu, H., Song, W., Guo, G., & Dou, K. (2009) · Pharmaceutical Research · doi:10.1007/s11095-009-9889-z · Cited by 99
“The amount of evidence points to hypoxia as a potent physiological stimulus that promotes tumor progression, driving genetic change and selecting for malignant phenotypes (3,4, 6 ).”
BackgroundMdm2 and HIF‐1α interaction in tumor cells during hypoxia
Nieminen, A., Qanungo, S., Schneider, E. A., Jiang, B., & Agani, F. H. (2005) · Journal of Cellular Physiology · doi:10.1002/jcp.20406 · Cited by 88
Martin, S. K., Diamond, P., Williams, S. A., To, L. B., Peet, D. J., Fujii, N., Gronthos, S., Harris, A. L., & Zannettino, A. C. W. (2009) · Haematologica · doi:10.3324/haematol.2009.015628 · Cited by 105
Radiopharmaceuticals in Preclinical and Clinical Development for Monitoring of Therapy with PET
Dunphy, M. P., & Lewis, J. S. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057281 · Cited by 94
Mitochondrial Regulation of Oxygen Sensing
Chandel, N. S. (2010) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-60761-500-2_22 · Cited by 91
A role for hypoxia and hypoxia-inducible transcription factors in tumor physiology
Acker, T., & Plate, K. H. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0355-1 · Cited by 112
“In vivo highly apoptotic regions overlapped with hypoxic areas in wt p53 tumors, while only little apoptosis in hypoxic areas of p53 deficient tumors was reported [152].”
BackgroundNon-Invasive PET and Spect Imaging of Tissue Hypoxia Using Isotopically Labeled 2-Nitroimidazoles
Koch, C. J., & Evans, S. M. (2003) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-0205-0_47 · Cited by 94
Self-citationDachs, G. U., & Chaplin, D. J. (1998) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(98)80046-5 · Cited by 100
Hdm2 Recruits a Hypoxia-Sensitive Corepressor to Negatively Regulate p53-Dependent Transcription
Mirnezami, A., Campbell, S. J., Darley, M., Primrose, J. M., Johnson, P., & Blaydes, J. P. (2003) · Current Biology · doi:10.1016/s0960-9822(03)00454-8 · Cited by 93
“Hypoxic stress induces a p53-dependent apoptotic response, and in many types of cancer may be responsible for the positive growth advantage of tumour cells in which the p53 gene is mutated [32].”
Rupinder, S. K., Aulakh, G. K., & Singh, M. (2007) · Vascular Pharmacology · doi:10.1016/j.vph.2007.01.006 · Cited by 116
Ubiquitin, E6-AP, and Their Role in p53 Inactivation
Scheffner, M. (1998) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(98)00003-5 · Cited by 111
MCL-1–dependent leukemia cells are more sensitive to chemotherapy than BCL-2–dependent counterparts
Brunelle, J. K., Ryan, J., Yecies, D., Opferman, J. T., & Letai, A. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200904049 · Cited by 87
“Conditions which often occur in cancer, such as growth factor and/or oxygen deprivation, can sensitize MYC-expressing cells to apoptosis (Evan et al., 1992; Graeber et al., 1996; Brunelle et al., 2004).”
BackgroundHypoxia attenuates the p53 response to cellular damage
Achison, M., & Hupp, T. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206434 · Cited by 107
“The first significant difference is that hypoxia was reported previously to induce p53-dependent apoptosis (Graeber et al., 1996; Giaccia and Kastan, 1998).”
BackgroundResultGieling, R. G., Parker, C. A., Costa, L. A. D., Robertson, N., Harris, A. L., Stratford, I. J., & Williams, K. J. (2012) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.3109/14756366.2012.736979 · Cited by 94
Hypoxia and Regulation of Cancer Cell Stemness
Yun, Z., & Lin, Q. (2014) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4614-5915-6_2 · Cited by 89
“Hypoxic tumor cells seem to be more aggressive, with reduced apoptosis (Graeber et al. 1996), increased drug-resistance (Wartenberg et al. 2003; Comerford et al. 2002), and increased metastatic potential (Rofstad 2000; Subarsky and Hill 2003).”
BackgroundJameson, M. B., Rischin, D., Pegram, M. D., Gutheil, J. C., Patterson, A. V., Denny, W. A., & Wilson, W. R. (2009) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-009-1188-1 · Cited by 102
“selection of p53-defective tumor cells [ 7 ], requirement of oxygen for optimal drug or radiation-induced DNA damage [8–10], and hypoxia-induced up-regulation of genes involved in drug resistance [11–14].”
Backgroundp53 tumour suppressor gene polymorphism is associated with recurrent implantation failure
Kay, C., Jeyendran, R., & Coulam, C. B. (2006) · Reproductive BioMedicine Online · doi:10.1016/s1472-6483(10)60635-9 · Cited by 92
Oncogenic resistance to growth-limiting conditions
Blagosklonny, M. V. (2002) · Nature reviews. Cancer · doi:10.1038/nrc743 · Cited by 92
“cgi?Q=hif1a%20or%20hif3a%20not%20flj14033&ORG=Hs">hypoxia-inducible factor, loss of sensitivity to inhibitors of the cell cycle, loss of p53, resistance to apoptosis and a highly metastatic phenotyp”
BackgroundExpression of hypoxia-inducible genes in tumor cells
Kress, S., Stein, A., Maurer, P., Weber, B., Reichert, J., Buchmann, A., Huppert, P. E., & Schwarz, M. (1998) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s004320050175 · Cited by 97
“Mutation of the p53 gene has been suggested to confer a survival advantage to the mutated tumor cells under conditions of very low oxygen (Graeber et al. 1996).”
BackgroundRedox-Based Escape Mechanism from Death: The Cancer Lesson
Pani, G., Giannoni, E., Galeotti, T., & Chiarugi, P. (2009) · Antioxidants & Redox Signaling · doi:10.1089/ars.2009.2739 · Cited by 91
“Interestingly, hypoxia, inflammation, and resistance to chemoradiation therapy have all been mechanistically linked to an increased risk of tumor dissemination (30, 36, 51, 92).”
Smith, K. J., Williams, J. P., Corbett, D., & Skelton, H. G. (2001) · The American Journal of Surgical Pathology · doi:10.1097/00000478-200104000-00005 · Cited by 93
Vascular Morphogenesis and Remodeling in a Human Tumor Xenograft
Patan, S., Tanda, S., Roberge, S., Jones, R. C., Jain, R. K., & Munn, L. L. (2001) · Circulation Research · doi:10.1161/hh2001.097872 · Cited by 92
Gene-Directed Enzyme Prodrug Therapy
Niculescu‐Duvaz, I., Spooner, R. A., Marais, R., & Springer, C. J. (1998) · Bioconjugate Chemistry · doi:10.1021/bc970116t · Cited by 92
Nagy, J. D. (2005) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2005.2.381 · Cited by 104
“Evidence for this conclusion comes from studies of p53-deflcient cells in culture, which commit apoptosis less frequently than intact wild-type cells in hypoxic environments [ 47 , 99].”
BackgroundHypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1α, GLUT1, and CAIX
Chen, C., Chu, J., Su, W., Huang, S.-C., & Lee, W. (2010) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-010-0938-0 · Cited by 105
“transporters (e.g., CAIX), by acquiring p53 mutations or overexpression of the apoptosis-inhibitor protein Bcl-2, all of which substantially reduce acid-mediated cell death [ 34 ].”
BackgroundSonveaux, P., Dessy, C., Brouet, A., Jordan, B. F., Grégoire, V., Gallez, B., Balligand, J., & Feron, O. (2002) · The FASEB Journal · doi:10.1096/fj.02-0487fje · Cited by 89
“, access to O2 and nutrients) to more easily re-grow after X-ray exposure? Alternatively (but not exclusively), is the tumor vasculature playing a role in stimulating oxygenation after each fractionated irradiation and therefore taking an active part in the treatment? Could this be exploited to tailor anti-cancer stra…”
BackgroundLe, Q.-T., Harris, J., Magliocco, A. M., Kong, C. S., Diaz, R., Shin, B., Cao, H., Trotti, A., Erler, J. T., Chung, C. H., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6003 · Cited by 86
“local failure, it has also been implicated in the development of distant metastasis.(4,5) Gene expression”
BackgroundSelf-citationStoichiometric Phosphorylation of Human p53 at Ser315Stimulates p53-dependent Transcription
Blaydes, J. P., Luciani, M. G., Pospisilova, S., Ball, H. M.-L., Vojtesek, B., & Hupp, T. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m003485200 · Cited by 90
Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences
Broxterman, H. J., Lankelma, J., & Hoekman, K. (2003) · Drug Resistance Updates · doi:10.1016/s1368-7646(03)00026-8 · Cited by 96
A Hypoxia-Regulated Adeno-Associated Virus Vector for Cancer-Specific Gene Therapy
Ruan, H., Sutt, H., Hu, L. J., Lamborn, K. R., Kan, Y. W., & Deen, D. F. (2001) · Neoplasia · doi:10.1038/sj.neo.7900157 · Cited by 91
“For example, hypoxia in solid tumors mediates selection of cells with diminished apoptotic potential and with genetic alterations such as loss of the p53 tumor suppressor gene or overexpression of the apoptotic inhibitor protein Bcl -2 [ 8 ].”
BackgroundCurrent Status of Knowledge and Critical Issues in Tumor Oxygenation
Vaupel, P. W., Thews, O., Kelleher, D. K., & Hoeckel, M. (1998) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-4863-8_70 · Cited by 91
Bell, E. L., & Chandel, N. S. (2007) · Essays in Biochemistry · doi:10.1042/bse0430017 · Cited by 90
Oxygen, Epigenetics and Stem Cell Fate
Okazaki, K. M., & Maltepe, E. (2005) · Regenerative Medicine · doi:10.2217/17460751.1.1.71 · Cited by 97
Reyes, G., Villanueva, A., García, C., Sancho, F. J., Piulats, J. M., Lluı́s, F., & Capellá, G. (1996) · PubMed · Cited by 90
Relationship of hypoxia to metastatic ability in rodent tumours
Jaeger, K. D., Kavanagh, M.-C., & Hill, R. P. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1743 · Cited by 89
“Other investigators have reported hypoxia-mediated increased mutation frequencies in tumours (Reynolds et al, 1996) and selection of cells deficient in genes of normal regulatory pathways (Graeber et al, 1996; Kim et al, 1997).”
BackgroundTargeting hypoxia tolerance in cancer
Wouters, B. G., van den Beucken, T., Magagnin, M. G., Lambin, P., & Koumenis, C. (2004) · Drug Resistance Updates · doi:10.1016/j.drup.2003.12.004 · Cited by 96
Apoptosis in the placenta of pregnancies complicated with IUGR
Erel, C. T., Dane, B., Calay, Z., Kaleli, S., & Aydinli, K. (2001) · International Journal of Gynecology & Obstetrics · doi:10.1016/s0020-7292(01)00373-3 · Cited by 90
A microwell array device capable of measuring single-cell oxygen consumption rates
Molter, T. W., McQuaide, S. C., Suchorolski, M. T., Strovas, T. J., Burgess, L. W., Meldrum, D. R., & Lidstrom, M. E. (2008) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2008.10.036 · Cited by 88
“[43–45]”
Hypoxia in the thymus: role of oxygen tension in thymocyte survival
Hale, L. P., Braun, R. D., Gwinn, W. M., Greer, P. K., & Dewhirst, M. W. (2002) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00682.2001 · Cited by 87
Disruption of actin microfilaments by cytochalasin D leads to activation of p53
Rubtsova, S. N., Kondratov, R. V., Kopnin, P., Chumakov, P. M., Kopnin, B. P., & Vasiliev, J. M. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)00692-9 · Cited by 103
Natural Product-Based Inhibitors of Hypoxia-Inducible Factor-1 (HIF-1)
Nagle, D., & Zhou, Y.-D. (2006) · Current Drug Targets · doi:10.2174/138945006776054979 · Cited by 88
Matas, D., Sigal, A., Stambolsky, P., Milyavsky, M., Weisz, L., Schwartz, D., Goldfinger, N., & Rotter, V. (2001) · The EMBO Journal · doi:10.1093/emboj/20.15.4163 · Cited by 88
Büchler, P., Reber, H. A., Lavey, R. S., Tomlinson, J. S., Büchler, M. W., Frieß, H., & Hines, O. J. (2004) · Journal of Surgical Research · doi:10.1016/j.jss.2004.02.014 · Cited by 88
Goh, V., Halligan, S., Wellsted, D. M., & Bartram, C. I. (2008) · European Radiology · doi:10.1007/s00330-008-1128-1 · Cited by 88
Clarke, K., Smith, K. J., Gullick, W., & Harris, A. L. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1805 · Cited by 89
“It may be that splice variant is specifically selected by the hypoxic mic environment as are mutations of p53 (Graeber et al, 1996) have previously shown that the hypoxic stress pathway regu by hypoxic inducible factor-1 alpha is critical for in vivo growth tumours (Maxwell et al, 1997) and…”
BackgroundPatterson, L. H. (2002) · Drug Metabolism Reviews · doi:10.1081/dmr-120005659 · Cited by 86
“In concert with this, hypoxia in tumors is a selection pressure for mutated p53, which results in cells becoming unresponsive to apoptosis.([3]) This is consistent with the resistance phenotype of hypoxic tumor cells.”
ResultPharmacokinetics of [18F]FETNIM: a potential marker for PET.
Grönroos, T. J., Eskola, O., Lehtiö, K., Minn, H. R. I., Marjamäki, P., Bergman, J., Haaparanta‐Solin, M., Forsback, S. J., & Solin, O. H. (2001) · PubMed · Cited by 88
Structure–based rescue of common tumor–derived p53 mutants
Wieczorek, A. M., Waterman, J. L. F., Waterman, M. J. F., & Halazonetis, T. D. (1996) · Nature Medicine · doi:10.1038/nm1096-1143 · Cited by 88
Jankovic, B., Aquino‐Parsons, C., Raleigh, J. A., Stanbridge, E. J., Durand, R. E., Banath, J. P., MacPhail, S. H., & Olive, P. L. (2006) · Cytometry Part B: Clinical Cytometry · doi:10.1002/cyto.b.20086 · Cited by 87
Targeting solid tumors with non‐pathogenic obligate anaerobic bacteria
Taniguchi, S., Fujimori, M., Sasaki, T., Tsutsui, H., Shimatani, Y., Seki, K., & Amano, J. (2010) · Cancer Science · doi:10.1111/j.1349-7006.2010.01628.x · Cited by 85
Metadata
- Authors
- Graeber, T. G., Osmanian, C., Jacks, T., Housman, D. E., Koch, C. J., Lowe, S. W., & Giaccia, A. J.
- Affiliations
- Stanford Medicine (US)
- Howard Hughes Medical Institute (US)
- Massachusetts Institute of Technology (US)
- University of Pennsylvania (US)
- Cold Spring Harbor Laboratory (US)
- Venue
- Nature
- Published
- 1996-01
- Volume
- 379
- Issue
- 6560
- Pages
- 88-91
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2028999918
- Cited by
- 2,300
- References
- 31
- Citations by year
- 2026: 7 · 2025: 13 · 2024: 16 · 2023: 30 · 2022: 27 · 2021: 55 · 2020: 39 · 2019: 37 · 2018: 37 · 2017: 51 · 2016: 56 · 2015: 56 · 2014: 41 · 2013: 70 · 2012: 78
- FWCI
- 52.76
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cell death mechanisms and regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- tumor hypoxia, apoptosis, solid tumors, p53, Bcl-2, p53 deficiency, tumor necrosis, tumor heterogeneity, tumor suppressor
- MeSH terms
- Animals, Cell Line, Transformed, Cell Transformation, Neoplastic, Neoplasm Transplantation, Neoplasms, Oxygen, Proto-Oncogene Proteins, Receptors, Estrogen, Tamoxifen, Cell Hypoxia, Genes, p53, Proto-Oncogene Proteins c-myc, Apoptosis, Proto-Oncogene Proteins c-bcl-2, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.